^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersBIOMARKER:
EGFR exon 19 deletion
i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related tests:
1d
COMPEL: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
P3, N=98, Active, not recruiting, AstraZeneca | Trial completion date: Jun 2026 --> Jun 2027
Trial completion date
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
|
cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed
1d
ML41701: A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors. (clinicaltrials.gov)
P2, N=22, Completed, National Taiwan University Hospital | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Feb 2026 | Trial primary completion date: Dec 2024 --> Feb 2026
Trial completion • Trial completion date • Trial primary completion date • IO biomarker
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
|
Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • pemetrexed
2d
Mutation-Specific Response to Ramucirumab in EGFR-Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study). (PubMed, JTO Clin Res Rep)
A previous analysis of the RELAY phase 3 liquid biopsy addendum demonstrated suppressed EGFR-activating mutation allele count, increased total cell-free DNA (cfDNA) concentration, and shortened cfDNA fragment size with ramucirumab (RAM) plus erlotinib (ERL) versus placebo (PL) plus ERL in patients with EGFR-mutated NSCLC. This updated analysis revealed differences in total cfDNA concentration and T790M mutation rates between ex19del and L858R. RAM plus ERL may exhibit greater antitumor effects on L858R, supporting the favorable survival benefits observed previously in patients with a L858R.
P3 data • Journal • Liquid biopsy
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
|
erlotinib • Cyramza (ramucirumab)
3d
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=60, Recruiting, Jonsson Comprehensive Cancer Center | Not yet recruiting --> Recruiting
Enrollment open
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • MET overexpression • EGFR exon 20 mutation
|
CONFIRM anti-Total c-MET (SP44) Rabbit Monoclonal Primary Antibody • VENTANA® MET (SP44) RxDx Assay
|
Tagrisso (osimertinib) • Emrelis (telisotuzumab vedotin-tllv)
4d
Polycationic dendrimers synergizes with gefitinib to overcome EGFREx19Del-driven resistance in non-small-cell lung cancer. (PubMed, Discov Oncol)
The use of complex dendrimer systems allows precise modulation of membrane-targeted interactions and intracellular signaling, providing mechanistic insights into overcoming EGFREx19Del-driven resistance. Overall, these findings highlight the translational potential of integrating membrane-targeted nanotherapeutics with EGFR-directed therapies to improve outcomes in NSCLC patients.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • EGFR mutation • EGFR exon 19 deletion
|
gefitinib
5d
Dual-site PGM-based point-of-care detection of EGFR exon 19 deletion with an endogenous internal control. (PubMed, Biosens Bioelectron)
Its feasibility was further demonstrated using cell-derived genomic DNA and serum-containing samples. These results indicate that the proposed platform provides an accessible and practical strategy for decentralized EGFR 19del testing.
Journal
|
EGFR (Epidermal growth factor receptor) • FEN1 (Flap Structure-Specific Endonuclease 1)
|
EGFR exon 19 deletion
5d
RAMOSE: Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
P2, N=160, Active, not recruiting, Xiuning Le | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Tagrisso (osimertinib) • Cyramza (ramucirumab)
7d
Almonertinib-Induced Interstitial Lung Disease in an NSCLC Patient Harboring an EGFR Ex19del Mutation: A Case Report. (PubMed, Case Rep Oncol)
Immediate discontinuation of almonertinib combined with intravenous methylprednisolone resulted in significant clinical and radiological improvement within 7 days. This case highlights two important clinical implications: (1) almonertinib-associated ILD can rapidly progress to a life-threatening condition and (2) occupational inhalational exposures (e.g., dust and smoking) have been directly and indirectly implicated as potential risk factors for EGFR-TKI-induced pulmonary toxicity in prior studies and may have contributed to the outcome in this case. Clinicians should maintain heightened vigilance for respiratory complications during almonertinib therapy, particularly in patients with preexisting pulmonary risk factors.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 19 deletion
|
Ameile (aumolertinib) • methylprednisolone sodium succinate
7d
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. (clinicaltrials.gov)
P1, N=56, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Jan 2026 --> Jan 2028
Trial primary completion date
|
STK11 (Serine/threonine kinase 11)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
|
Libtayo (cemiplimab-rwlc) • Kevzara (sarilumab)
8d
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2/3, N=854, Recruiting, AbbVie | Trial completion date: Dec 2031 --> Nov 2036
Trial completion date • Adverse events
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • telisotuzumab adizutecan (ABBV-400)
9d
LuCa-MERIT-1: Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
P1, N=320, Recruiting, BioNTech SE | N=156 --> 320
Enrollment change • First-in-human
|
ALK (Anaplastic lymphoma kinase) • LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • RET rearrangement
|
Tagrisso (osimertinib) • carboplatin • paclitaxel • docetaxel • Libtayo (cemiplimab-rwlc) • gotistobart (BNT316) • BNT116
9d
RAISE: The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer (clinicaltrials.gov)
P=N/A, N=60, Recruiting, Hunan Province Tumor Hospital | Not yet recruiting --> Recruiting | Trial completion date: Jun 2027 --> Apr 2026 | Trial primary completion date: Dec 2026 --> Mar 2026
Enrollment open • Trial completion date • Trial primary completion date • Real-world evidence
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Tagrisso (osimertinib)
Share via
